The most studied copper peptide is GHK-Cu (glycyl-L-histidyl-L-lysine), a small copper-binding peptide, naturally present in human plasma
Some patients report changes in comfort, mobility, or recovery within the first few weeks, but results vary and should not replace diagnosis, imaging, rehab, or medical treatment
The discontinuation rate due to adverse events was 6% for CagriSema versus 3.7% for placebo
Once senescent cells are removed, the downstream benefits continue to develop as: SASP-driven inflammation progressively resolves Stem cell niches, previously suppressed by SASP factors, may reactivate Tissue remodeling and repair processes engage in cleared areas The paracrine senescence cascade (where SASP converts healthy cells to senescent ones) is interrupted In mouse models, improvements in kidney function and physical fitness persisted and in some cases continued to develop during the weeks following treatment cessation (Baar et al., 2017)